Cure8 research brief
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein delivery for Crohn’s disease and ulcerative colitis while reducing systemic side effects.
Researchers and clinicians working on IBD immunotherapy, patients interested in emerging cell-based biologic delivery strategies, and people receiving or considering systemic biologic therapies.
This is a funded NIH project describing development of engineered B cells/plasma cells targeted to the gut to deliver therapeutic proteins (for example IL-10) as a potential IBD therapy.
The aims are to study how engineered B cells home to small and large intestine, integrate into host immune responses, and function as long-lived antibody- or protein-secreting cells to deliver immunomodulators.
The project emphasizes B cell receptor (BCR) specificity to direct cells to gut tissues, use of engineered long-lived plasma cells for localized biologic delivery, and preclinical/translational modeling. It is framed as mechanistic, preclinical research to inform future cell-based therapies rather than reporting human trial results.
this entry is a project record describing planned and ongoing funded research. It does not present clinical results or an approved therapy; translation to patients will require additional development and clinical testing.
This is a funded research project (NIH Reporter project record) describing preclinical/translational aims. It does not report clinical trial data or clinical efficacy. Early-stage mechanistic work in animals and models is implied; human safety and effectiveness are not established.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Allergy and Infectious Diseases - R01AI201425 - $911,271
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...
